Experimental drugs
154 articles and resources in this section.
- 5-MeO-DMT (mebufotenin) · Alcohol use disorder
Twelve participants received BPL-003 alongside a cognitive behavioral program. Six remained abstinent during the 12-week follow-up. Individual outcomes varied, including…
- 5-MeO-DMT (mebufotenin) · Anxiety and depression with cognitive impairment
The registered study examined anxiety, depressive symptoms and cognition in people with mild cognitive impairment or early Alzheimer-type impairment.
- 5-MeO-DMT (mebufotenin) · Anxiety and depressive symptoms
Adults reporting moderate to high symptoms, without a formal psychiatric diagnosis, participated in a tolerability study. The authors described transient nausea and headache…
- 5-MeO-DMT (mebufotenin) · Bipolar II depression
Six participants with bipolar II disorder and a current depressive episode had a mean 16.8-point decline in MADRS scores by day eight.
- 5-MeO-DMT (mebufotenin) · Catatonia
No clinical trial or therapeutic case report for catatonia was identified in the reviewed sources. The positive phase 2 studies measured depressive symptoms in selected adults.
- 5-MeO-DMT (mebufotenin) · Obsessive-compulsive symptoms and other self-reported conditions
Among survey respondents reporting OCD, 53% described improvement after use. Participants also reported changes in traumatic stress, depression, anxiety and substance-use…
- 5-MeO-DMT (mebufotenin) · Postpartum depression
All ten participants reached the depression-scale remission threshold at day eight. Headache was the most common adverse event. The study reported no serious adverse events.
- 5-MeO-DMT (mebufotenin) · PTSD symptoms and risky alcohol use in veterans
Among 45 veterans in a program who screened positive for risky drinking, average alcohol-risk scores fell from 7.2 to 3.6 at one month and were 4.0 at six months. Related…
- 5-MeO-DMT (mebufotenin) · Schizophrenia
The reviewed studies did not establish a benefit for positive, negative or cognitive symptoms of schizophrenia. The large phase 2 depression trial selected a different population.
- 5-MeO-DMT (mebufotenin) · Treatment-resistant depression
With GH001, 23 of 40 treated participants reached remission by day eight compared with none of 41 on placebo. The active group improved 15.5 MADRS points more than placebo. A…
- All evidence
Browse the individually summarized evidence. Search a drug, condition, study design, outcome or trial identifier.
- Amantadine · Catatonia
Three patients who had nearly stopped moving recovered movement after amantadine. In a separate hospital cohort, 57 adults received either amantadine or memantine. Their mean…
- Aripiprazole, olanzapine and other antipsychotics · Catatonia, often with psychosis
Reviewers classified 60% of reported treatment attempts as beneficial, 29% as neutral and 11% as harmful. Reports for aripiprazole and olanzapine were mixed. Harm predominated…
- Ayahuasca · Catatonia
This review identified no human trial or therapeutic case report supporting ayahuasca for catatonia. Ayahuasca is a variable botanical mixture, commonly containing DMT and…
- Ayahuasca · Depression and anxiety after cancer diagnosis
Depression and anxiety scores fell after treatment and the changes persisted through three weeks. No serious adverse events were reported in this small group.
- Ayahuasca · Eating disorders and body image
Sixteen people with prior eating disorder diagnoses described experiences during ceremonial use. Some related these experiences to recovery. A separate registered study…
- Ayahuasca · Emotional dysregulation and borderline personality traits
Some measures of emotional dysregulation improved following participation, including among people with elevated borderline personality traits.
- Ayahuasca · Functional (dissociative) seizures
A Brazilian study plans to follow seizure frequency and related psychiatric measures in 15 patients with functional seizures, also called psychogenic nonepileptic seizures.
- Ayahuasca · Harmful alcohol use
Participants reported fewer drinking days two to three weeks later. The finding lost statistical significance when the researchers corrected for multiple comparisons.
- Ayahuasca · Inattention and hyperactivity
Self-reported inattention, hyperactivity and impulsivity decreased following the retreat. Only four participants reported having an ADHD diagnosis.
- Ayahuasca · Post-traumatic stress disorder
A case series followed eight veterans with PTSD symptoms after a program involving ayahuasca. In the corrected report, five of seven with evaluable checklist scores showed…
- Ayahuasca · Premenstrual symptoms
Researchers plan to compare ayahuasca and esketamine in 20 women to examine premenstrual symptoms.
- Ayahuasca · Schizophrenia, psychosis and mania
One patient developed sustained psychotic symptoms after ayahuasca and received antipsychotic treatment. Another developed a manic episode after its use in a context of…
- Ayahuasca · Severe grief after bereavement
Participants receiving ayahuasca plus meaning reconstruction therapy reported greater reductions in grief severity than those receiving therapy alone or no intervention.
- Ayahuasca · Social anxiety disorder
Participants receiving ayahuasca rated their own public-speaking performance more positively during follow-up. The improvement was specific to self-appraisal. Physical…
- Ayahuasca · Substance use disorders
The Takiwasi program followed participants after treatment combining ayahuasca, psychotherapy and residential care. The investigators reported improvements in several…
- Ayahuasca · Suicidal ideation and acute safety
In the 29-person depression trial, the difference in suicidal thinking between groups did not reach statistical significance (p = .088). In another trial, an 18-year-old…
- Ayahuasca · Treatment-resistant depression
By day seven, 64% of participants given ayahuasca met the depression-response criterion compared with 27% on placebo. Remission occurred in 36% versus 7%, with greater…
- Bromocriptine · Malignant catatonia
A 19-year-old with episodes of excitement and stupor and unstable autonomic function recovered after clinicians used a benzodiazepine and bromocriptine.
- Cannabidiol (CBD) · Schizophrenia
In one six-week study of 88 patients, CBD provided a 1.4-point advantage on the PANSS positive-symptom subscale. Another small trial in stable outpatients found no significant…
- Cannabis exposure · Catatonia after cannabis exposure
One report describes recurrence associated with resumed cannabis exposure. Other reports describe acute symptoms requiring hospital assessment and treatment.
- Carbamazepine · Catatonia
Four people had complete resolution, one had partial relief and four showed no significant improvement. Six had initially responded completely but only briefly to lorazepam.
- Catatonia
Start with reports and studies that actually concern catatonia. Read each entry’s clinical setting to distinguish treatment, an underlying illness, anesthesia and an adverse…
- Clozapine · Catatonia with schizophrenia
Among 182 reported patients, 119 had schizophrenia. More than four in five had at least partial improvement in catatonia while receiving clozapine.
- Clozapine · Clozapine-withdrawal catatonia
Patients have developed catatonia after suddenly stopping clozapine. Case reports describe recovery after clinicians reintroduced clozapine or used electroconvulsive therapy…
- Corticosteroids, IVIg and other immunotherapies · Catatonia in anti-NMDA receptor encephalitis
A pediatric review identified catatonic features in 49 of 57 published cases. In patients described as receiving treatment for catatonia, improvement followed initiation of…
- Deuterated DMT (HLP004 / CYB004) · Generalized anxiety disorder
Thirty-six adults with persistent anxiety during antidepressant treatment were randomized between two levels of a chemically modified DMT analog. The sponsor reported about a…
- Dexmedetomidine · Severe agitation in excited catatonia
In one patient, agitation settled enough for clinicians to complete a medical evaluation and obtain emergency authorization for ECT. The reports illustrate a role for…
- DMT & related preparations
Read N,N-DMT, 5-MeO-DMT and ayahuasca separately. Each entry names the preparation studied, the diagnosis, the outcome and the limits of the evidence.
- Emraclidine · Acute schizophrenia
Neither trial showed a statistically significant improvement over placebo on the prespecified PANSS total score.
- Esketamine · Catatonia in major depression after ECT
A woman aged 55 had persistent catatonia after diazepam and bilateral electroconvulsive therapy (ECT). With intranasal esketamine, her catatonia score fell from 20 to 5 by…
- Esketamine · Major depression with acute suicidal ideation or behavior
In ASPIRE I and II, adults hospitalized with major depression and suicidal intent received comprehensive care. Adding esketamine produced greater improvement in overall…
- Esketamine · Postpartum depression prevention in women with prenatal symptoms
Among 364 mothers with prenatal depressive symptoms, a trial tested IV esketamine immediately after childbirth. At six weeks, a major depressive episode was diagnosed in 6.7%…
- Esketamine · Treatment-resistant depression in adults
Spravato nasal spray has U.S. approval for adult treatment-resistant depression, alone or alongside an oral antidepressant. In a four-week trial of 378 treated participants…
- Evenamide · Treatment-resistant schizophrenia
The sponsor announced completion of enrollment in October 2026, with 618 people across 19 countries. The update supplied no randomized primary efficacy result.
- Experimental drugs
Explore what happened when a drug was studied in a person with catatonia, in someone living with schizophrenia, or in a different psychiatric condition. Each finding…
- Future possibilities
Some people report retained awareness while unable to speak. A patient-selected way to signal a need may improve comfort after stabilization.
- Future research questions
Some people report retained awareness while unable to speak. A patient-selected way to signal a need may improve comfort after stabilization.
- Iclepertin · Cognitive impairment associated with schizophrenia
Over 26 weeks, the pooled difference on the standardized cognitive battery was 0.13 T-score points, with a 95% confidence interval from −0.40 to 0.65. No meaningful cognitive…
- Intravenous immunoglobulin (IVIg) · Catatonic signs in Down syndrome regression disorder
At 12 weeks, the IVIg and lorazepam groups both did better than the untreated group on measured outcomes. The mean catatonia score was 2.24 points lower with IVIg than…
- Ketamine & esketamine
Follow the individual catatonia reports, including the response over time, then compare them with anesthesia, symptom-challenge experiments and depression trials.
- Ketamine and esketamine · Catatonia across several diagnoses
A review found 10 adults described in nine papers. All had some improvement. Six had a Bush–Francis Catatonia Rating Scale score. Four of those six had at least a 50% score…
- Ketamine and esketamine · Catatonia during an ECT course
A patient with severe depression, dementia and catatonic stupor recovered from catatonia over 16 ECT sessions given under S-ketamine anesthesia. A separate report examined a…
- Ketamine and esketamine · Catatonia in schizoaffective disorder
A 63-year-old woman with mutism, little movement and poor intake regained everyday activities after sublingual ketamine and later intranasal esketamine. She was briefly…
- Ketamine and esketamine · Depressive and negative symptoms in schizophrenia
In a pilot involving clozapine-resistant schizophrenia with treatment-resistant depression, mood scores improved briefly. Depression recurred by day 21, and a second course…
- Ketamine and esketamine · Depressive episodes with psychotic features
A 2025 review found 79 patients across ten studies, including 60 with unipolar and 19 with bipolar depression with psychotic features. Several studies described improved…
- Ketamine · Alcohol use disorder
Among 96 adults with severe alcohol use disorder, those assigned ketamine had about 10 percentage points more abstinent days over six months than those assigned saline. The…
- Ketamine · Borderline personality disorder
Among 22 adults with borderline personality disorder, ketamine did not significantly outperform midazolam for suicidal thoughts, depression, anxiety or overall borderline…
- Ketamine · Cannabis use disorder
Eight adults received ketamine together with motivational enhancement and mindfulness-based relapse prevention. Their self-reported cannabis use fell over the six-week study.
- Ketamine · Catatonia in bipolar depression when ECT was medically difficult
Two older women regained their usual level of functioning. One had severe cardiomyopathy, and the other developed a pulmonary embolism that interrupted ECT. Their respective…
- Ketamine · Catatonia in depression with psychotic symptoms
A French team described a 65-year-old woman treated with ketamine and lorazepam while access to ECT was limited. Her catatonia score fell from 38 to 1 in the first week. The…
- Ketamine · Catatonia in schizophrenia
A 77-year-old woman with schizophrenia was immobile and mute. Conventional medication had provided inadequate relief, and ECT was unavailable. The authors reported return of…
- Ketamine · Catatonia with food refusal in psychotic depression
A Colombian team described a woman with severe depression, food refusal and cardiovascular disease. After IV ketamine, clinicians reported that catatonic signs had resolved…
- Ketamine · Catatonia-like presentation in emergency care
A 23-year-old man abruptly stopped speaking and showed waxy flexibility. He became alert and spoke after ketamine in the emergency department. He later described a previous…
- Ketamine · Chronic catatonia in psychotic depression after ECT
A 56-year-old woman had persistent symptoms despite benzodiazepines and an extended course of ECT. Her catatonia score fell from 25 to 9 by discharge after IV ketamine. She…
- Ketamine · Cocaine use disorder
In 55 adults receiving mindfulness-based relapse prevention, 48% assigned to ketamine and 11% assigned to midazolam were abstinent during the final two weeks. Urine testing…
- Ketamine · Depression during psychiatric hospitalization
In KARMA-Dep 2, 65 psychiatric inpatients with depression were randomized to adjunctive ketamine or midazolam. Depression severity at the end of treatment did not differ…
- Ketamine · Eating disorders with co-occurring depression or anxiety
Five people received ketamine-assisted group psychotherapy alongside residential eating-disorder treatment. Four showed a clinically meaningful depression-score change and two…
- Ketamine · Hyperactive catatonia in autism and catatonia in Down syndrome regression disorder
In six autistic people with hyperactive catatonia, clinicians used ketamine to obtain IV access for 256 of 318 ECT sessions. A separate series involving five people with Down…
- Ketamine · Major depression in adolescents
In a trial of 17 adolescents with major depression, clinician-rated depression was lower at 24 hours after ketamine than after midazolam. Later assessments varied according to…
- Ketamine · Obsessive-compulsive disorder
Among 15 adults with frequent intrusive obsessions, four of eight who received ketamine first met the OCD response threshold at one week, compared with none of seven who…
- Ketamine · Opioid use disorder following heroin detoxification
An early trial compared two ketamine-assisted psychotherapy regimens after detoxification. A subsequent study reported one-year abstinence in 13 of 26 participants assigned to…
- Ketamine · Post-traumatic stress disorder
In a trial of 30 people with chronic PTSD, clinician ratings improved more after ketamine than midazolam over two weeks. In a separate trial of 158 veterans and service…
- Ketamine · Psychotic symptoms in schizophrenia
Researchers gave ketamine to volunteers to study psychosis. In one experiment involving 17 adults with schizophrenia and 18 healthy volunteers, ketamine briefly increased…
- Ketamine · Recurrent catatonia in major depression
A 44-year-old woman with repeated admissions improved after IV ketamine when catatonia persisted with lorazepam. Catatonic symptoms recurred approximately three months later.
- Ketamine · Refractory catatonia while awaiting ECT
A team reported that catatonia lifted after IV ketamine while legal proceedings delayed ECT. They were able to avoid a contemplated feeding-tube procedure before definitive ECT.
- Ketamine · Severe suicidal thoughts during hospitalization
In the French KETIS trial of 156 adults, 63% of those assessed in the ketamine group and 32% in the placebo group met the trial’s threshold for remission of suicidal thoughts…
- Ketamine · Social anxiety disorder and generalized anxiety disorder
In 18 adults with social anxiety, one clinician-administered scale favored ketamine, while a self-rated anxiety measure did not distinguish it from saline. A study of 12…
- Ketamine · Tobacco use disorder
In a ten-person saline-controlled pilot, smoking, craving and withdrawal did not differ significantly. A later 18-person crossover study with midazolam also found no…
- Ketamine · Treatment-resistant bipolar depression
A 2026 trial randomized 68 adults with bipolar I or II depression. At day 14, the ketamine group’s average depression score was 7.3 points lower than the midazolam group’s on…
- Ketamine · Treatment-resistant major depression without psychosis
In ELEKT-D, 55.4% of participants assigned to ketamine and 41.2% assigned to ECT met the short-term threshold for improvement in self-rated depression. Ketamine met the…
- Lamotrigine · Periodic catatonia
A clinician described fewer and less severe recurrent catatonic episodes during maintenance treatment with lamotrigine.
- Levodopa · Catatonic stupor
Historical reports describe return of movement in some people with catatonic stupor. In a small series, psychotic symptoms worsened despite improvement in movement.
- Lithium · Periodic catatonia
One patient with recurring episodes remained symptom-free for nine years while receiving lithium. Episodes returned after physicians stopped it because of toxicity associated…
- LSD (DT120/MM120) · Generalized anxiety disorder
The published phase 2b trial found a dose-response relationship in anxiety scores at four weeks. The sponsor subsequently reported that both pivotal trials met their 12-week…
- LSD (DT120/MM120) · Major depressive disorder
The sponsor reported an 8.1-point greater reduction on the Montgomery–Åsberg Depression Rating Scale at six weeks in Emerge.
- LSD (lysergide) · Adult attention-deficit/hyperactivity disorder
ADHD symptoms improved in both groups. The study found no statistically significant advantage for LSD over placebo.
- LSD (lysergide) · Alcohol use disorder
The pooled analysis favored LSD at the first follow-up, but the signal varied across follow-up intervals.
- LSD (lysergide) · Anxiety with or without life-threatening illness
Anxiety ratings improved more with LSD-assisted therapy in the controlled comparison. A subsequent observational follow-up described persistent improvement for some participants.
- LSD (lysergide) · Schizophrenia and catatonic features
Researchers described increased communication in some patients with catatonic features, but also transient intensification of agitation in some people with acute…
- MDMA
Read the findings from PTSD and other psychiatric studies alongside the schizophrenia tolerability study and reports of catatonia after ecstasy exposure.
- MDMA · Adjustment disorder in people with cancer and their partners
The study plans to enroll ten patient–partner pairs affected by cancer. It measures adjustment-disorder symptoms and relationship functioning after MDMA-assisted therapy.
- MDMA · Alcohol use disorder
Fourteen adults received MDMA-assisted psychotherapy after clinical detoxification. Participants reported substantially lower average alcohol consumption nine months later…
- MDMA · Anorexia nervosa and binge-eating disorder
A proposed multi-site study would have examined MDMA-assisted psychotherapy for restricting-type anorexia nervosa and binge-eating disorder.
- MDMA · Anxiety associated with a life-threatening illness
Eighteen patients with anxiety related to a life-threatening illness were randomized. Mean trait-anxiety scores fell by 23.5 points in the MDMA group and 8.8 with placebo. The…
- MDMA · Borderline personality disorder
Yale is examining short-term changes in self-reported social cognition in adults with borderline personality disorder after study-administered MDMA.
- MDMA · Bulimia nervosa
A Mount Sinai study compares two versions of MDMA-assisted therapy with standard care in bulimia nervosa. The main measure is the frequency of binge-eating episodes.
- MDMA · Catatonia after recreational ecstasy exposure
A 1993 report described low blood sodium and catatonic stupor after ecstasy. Later authors reported adolescent catatonia after recreational exposure and an adult with chronic…
- MDMA · Chronic pain in people with PTSD
Among 32 participants who completed pain assessments during a PTSD study, people starting with moderate or high pain reported less intense pain after therapy. Nine…
- MDMA · Co-occurring PTSD and alcohol use disorder
A 2026 pilot followed ten veterans with both diagnoses. PTSD severity fell and participants reported fewer heavy-drinking days. The authors judged the change in alcohol…
- MDMA · Dissociation, depression and sleep symptoms in PTSD
A 2026 review combined seven randomized trials of MDMA-assisted psychotherapy for PTSD. The pooled data suggested improvements in dissociative symptoms, depressive symptoms…
- MDMA · Eating-disorder symptoms in people with severe PTSD
Investigators examined changes in Eating Attitudes Test scores among people enrolled for severe PTSD. They reported exploratory differences favoring MDMA-assisted therapy on…
- MDMA · Major depressive disorder
Twelve adults with major depressive disorder took part in a feasibility study. Depression scores fell after treatment. A later publication followed the same participants to…
- MDMA · Obsessive-compulsive disorder
A Stanford study asks whether MDMA-assisted cognitive behavioral therapy improves obsessive-compulsive symptoms, measured using the Yale-Brown Obsessive Compulsive Scale. The…
- MDMA · Occupational distress in healthcare providers and first responders
One protocol includes healthcare workers and first responders with adjustment disorder or PTSD. Another focuses on well-being among mental healthcare providers.
- MDMA · Pathological narcissism
A University of Washington trial studies MDMA-assisted therapy in participants with pathological narcissism. The main measures include participants’ ratings on the…
- MDMA · Post-traumatic stress disorder (PTSD)
MAPP1 enrolled 90 adults with severe PTSD. MAPP2 enrolled 104 with moderate or severe PTSD. In both, the group assigned MDMA plus therapy had larger reductions in…
- MDMA · Postpartum PTSD with opioid use disorder
The University of New Mexico plans to study postpartum participants with both PTSD and opioid use disorder. The primary outcome concerns PTSD symptoms.
- MDMA · Psychosis after recreational ecstasy exposure
Clinicians describe persistent hallucinations, paranoia or disorganization beginning after reported recreational ecstasy use. In these reports MDMA exposure preceded symptoms…
- MDMA · PTSD and relationship functioning
A pilot integrated MDMA with conjoint therapy in six couples in which one partner had PTSD. A separate 2026 study in eight veterans and their partners also observed…
- MDMA · PTSD with moral injury
A study in veterans with PTSD and moral injury assesses PTSD symptoms and explores changes in relationships, hyperarousal and neural responses.
- MDMA · Schizophrenia · tolerability and social motivation
UCLA plans to study 20 adults with clinically stable schizophrenia. Investigators monitor disorganized speech, delusions and hallucinations and explore whether MDMA changes…
- MDMA · Social anxiety disorder
A trial of 20 adults with social anxiety disorder reported a larger 16-week improvement on the Liebowitz Social Anxiety Scale in participants assigned to immediate…
- MDMA · Social anxiety in autistic adults
Twelve autistic adults with substantial social anxiety entered the study. Eight were assigned MDMA-assisted psychotherapy and four received placebo with psychotherapy…
- MDMA · Social functioning in autistic adults · R-MDMA
Five autistic adults participated in a study of R-MDMA, one of the two mirror-image forms of MDMA. The sponsor described exploratory changes in rigidity and social engagement.
- Memantine · Catatonia
Three reports described recovery from catatonia associated with stroke or low blood sodium. In another patient with schizophrenia and persistent catatonia, communication…
- Memantine · Schizophrenia
A crossover study in 52 adults with symptoms despite clozapine found small improvements in memory and negative symptoms, such as diminished expression or motivation. A…
- Methylphenidate · Catatonia associated with bipolar disorder
A patient with bipolar disorder regained daily functioning after clinicians added methylphenidate following unsuccessful earlier treatments. Other reports describe stimulant…
- N,N-DMT · Alcohol use disorder
Yale’s trial plans to compare DMT with placebo alongside psychotherapy in 63 participants and follow drinking outcomes.
- N,N-DMT · Catatonia
The review found no therapeutic study of N,N-DMT for catatonia. A 1958 experiment in psychiatric patients described a patient becoming stuporous during DMT exposure. The…
- N,N-DMT · Depression and suicidal ideation
A registered phase 2b trial plans to enroll 140 people with major depression and measures depression severity and suicidal thinking. A separate 112-person study uses…
- N,N-DMT · Major depressive disorder
Among 34 adults, the DMT group improved by an estimated 7.35 points more than placebo on the Montgomery–Åsberg Depression Rating Scale (MADRS) at two weeks. The 95% confidence…
- N,N-DMT · Schizophrenia and psychosis
A 1958 series included 24 women, 20 with chronic schizophrenia. The authors noted temporary improvement in three participants but could not separate drug effects from clinical…
- N,N-DMT · Treatment-resistant depression
Twelve of 14 participants met the study’s response threshold at day seven, and eight met its remission threshold. Suicidal ideation also decreased during observation.
- Other catatonia drugs
These medicines have been reported in particular catatonia presentations, including persistent symptoms, specific underlying diseases and withdrawal states. Their place in…
- Other psychiatric drugs
Explore drug development for schizophrenia alongside other psychiatric uses of psychedelics. Each entry identifies the target symptom and whether the study found benefit, harm…
- Paper index
Browse the PubMed records identified in the reproducible catatonia searches. Index inclusion means the paper matched a search. Read its source and study design to see how the…
- Psilocybin (COMP360) · Post-traumatic stress disorder
PTSD scores decreased during the open-label study. The registered controlled comparison is designed to test whether symptom changes exceed those with a comparator.
- Psilocybin (including COMP360) · Treatment-resistant depression
The COMP360 sponsor reported that both pivotal trials met their six-week symptom endpoint and announced a US new drug application on November 9, 2026. EPISODE did not find a…
- Psilocybin · Alcohol use disorder
In the US trial, the average proportion of heavy-drinking days in the 32-week follow-up was 9.7% with psilocybin versus 23.6% with active placebo. The post-withdrawal study…
- Psilocybin · Anorexia nervosa
Investigators found that treatment and follow-up were feasible. Two participants experienced transient asymptomatic low blood sugar.
- Psilocybin · Bipolar II depression
Clinician-rated depression scores improved. Three participants experienced clinically notable psychiatric events involving hypomania or suicidal ideation, which resolved with…
- Psilocybin · Body dysmorphic disorder
The investigators observed a decline in body dysmorphic symptoms after the intervention.
- Psilocybin · Cancer-related anxiety and depressive distress
Each trial observed reductions in anxiety and depression before crossover, and many participants reported lasting improvement during follow-up.
- Psilocybin · Catatonia after psychedelic exposure
In one case, a previously communicative man became mute and needed help with eating. In another, heavy use preceded psychosis with catatonic signs in a person with…
- Psilocybin · Cocaine use disorder
Psilocybin recipients averaged about 29 percentage points more cocaine-abstinent days. They also had a longer time to first lapse.
- Psilocybin · Demoralization in older long-term AIDS survivors
Participants reported lower demoralization after treatment and at three months.
- Psilocybin · Major depressive disorder
Participants assigned to psilocybin had a greater reduction in depression scores through day 43.
- Psilocybin · Obsessive-compulsive disorder
At the end of eight weeks, 11 of 15 met the study response threshold and 6 met remission criteria on the OCD symptom scale.
- Psilocybin · Residual symptoms in schizoaffective disorder
The authors described improvements in depression for about three months and in apathy and reduced emotional expression for more than six months.
- Psilocybin · Tobacco use disorder
Participants assigned to psilocybin had over six times the odds of biochemically confirmed prolonged abstinence at six months.
- Risperidone · Catatonia with schizophrenia-spectrum illness
Fourteen hospitalized adults contributed to a three-week analysis. Both groups improved, but catatonia ratings improved more in the ECT group than in the risperidone group.
- Schizophrenia & psychosis
Look at what was measured in a schizophrenia-spectrum population, or in a study designed to model psychotic symptoms. The distinction matters for negative symptoms…
- Search methods
What was searched, how each item entered the Atlas, and which questions an entry can answer.
- Sodium oxybate · Catatonia
The Dutch Laborit study compares prescription sodium oxybate with lorazepam in hospitalized patients whose catatonia persists during initial treatment. Eligible underlying…
- Tofacitinib · Down syndrome regression disorder with possible catatonia
Three individuals with probable Down syndrome regression disorder showed improvement in several neurological domains during tofacitinib treatment. One showed improved ability…
- Topiramate · Catatonia
All four published patients experienced remission. In one, agitation returned during a medication interruption and improved after clinicians resumed topiramate and lorazepam.
- Trial finder
Search the registry snapshot by drug, indication, trial name or identifier. Open a record for its study design, its reported status and the original registration. For outcomes…
- Ulotaront (SEP-363856) · Acute schizophrenia
The early trial found a greater improvement in PANSS scores than placebo. In DIAMOND 1 and DIAMOND 2, neither trial met its primary symptom endpoint. A subsequent phase 3…
- Valproate · Excited or severe catatonia
One 38-year-old man with longstanding schizophrenia and recurrent severe catatonia improved during intravenous valproate treatment. His episodes included motor excitement as…
- What changed for patients?
The clearest early signal for ketamine in catatonia is a change families can recognize: some people began moving, speaking or eating again. Most published observations come…
- Xanomeline/trospium (Cobenfy) · Schizophrenia in adults
The pooled advantage over placebo was 9.9 points on the Positive and Negative Syndrome Scale (PANSS), a measure of overall schizophrenia symptoms. The FDA approved the…
- Xanomeline/trospium (Cobenfy) · Schizophrenia with inadequate response to current antipsychotic
At six weeks, the difference between groups in PANSS total score fell short of statistical significance.
- Zolpidem · Catatonia
Nineteen people had full remission, 48 showed partial improvement and 12 showed no response. Some reports describe a brief return of speech or movement, while others followed…